Core Viewpoint - The company is focusing on enhancing its core business segments, particularly in the fields of mental rehabilitation, pelvic floor rehabilitation, neurological rehabilitation, and medical aesthetics, aiming for growth and market share expansion in 2025 [2][3][4][5]. Business Segment Overview - **Mental Rehabilitation**: The company plans to leverage the MagNeuro ONE series products to increase market share and solidify its leading position in non-invasive neuroregulation [2]. - **Pelvic Floor Rehabilitation**: The company anticipates a stabilization in this segment through product iteration and transformation, with the high-frequency electrosurgical device becoming a new growth point [2]. - **Neurological Rehabilitation**: The company sees potential for growth due to low market share and plans to expand product categories and marketing efforts to enhance business scale [2]. - **Medical Aesthetics**: The company aims to enter the mainstream skin management market in 2025, focusing on a product matrix that includes skin, body, and intimate health solutions [2][4]. Policy Impact - The recent issuance of guidelines by the National Medical Insurance Administration for pricing in the neurotechnology sector is expected to support the company's investments in brain-computer interface technologies [3]. Women's Health Initiatives - The company is committed to expanding its product offerings in women's health, particularly in pelvic floor recovery, and aims to meet diverse health management needs throughout women's life cycles [4]. AI Integration - The company is actively integrating AI technologies into its product designs to enhance automation and intelligence, with applications in various therapeutic devices [7]. Rehabilitation Robotics - The company has developed a comprehensive range of rehabilitation robots that cater to various rehabilitation needs, focusing on intelligent and standardized solutions to improve recovery efficiency [8]. Silver Economy Strategy - The company is strategically positioned to benefit from the growing demand for rehabilitation services due to an aging population, with a diverse product matrix aimed at addressing the needs of elderly patients [9]. Financial Performance - The company reported a main revenue of 292 million yuan in Q3 2024, a year-on-year decrease of 12.06%, with a net profit of 78.17 million yuan, down 23.13% [14]. Market Ratings - Recent ratings from three institutions indicate a positive outlook, with two buy ratings and one hold rating, and a target price of 33.00 yuan [15]. Investment and M&A Plans - The company is exploring opportunities for external growth through mergers and acquisitions, particularly in related industry sectors, while maintaining a focus on internal growth [13].

Financial Performance - Total revenue for 2024 was CNY 400.06 million, a decrease of 13.45% compared to the previous year[3] - Operating profit decreased by 26.48% to CNY 109.13 million, while total profit fell by 26.02% to CNY 111.00 million[3] - Net profit attributable to shareholders was CNY 100.01 million, down 26.61% year-on-year, with a net profit excluding non-recurring gains and losses of CNY 83.80 million, a decline of 31.15%[3] - Basic earnings per share decreased by 26.30% to CNY 1.0509, and the weighted average return on equity dropped by 2.49 percentage points to 6.14%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,818.52 million, an increase of 0.69% year-on-year, while equity attributable to shareholders decreased by 0.08% to CNY 1,625.50 million[5] - The company's share capital increased by 39.56% due to a capital reserve conversion plan, resulting in a significant increase in the number of shares[7] Product and Market Strategy - The company achieved good sales results for its aesthetic medical products, including the shaping magnetic stimulation device and high-frequency electrosurgical device[6] - The company is focused on optimizing its marketing system to enhance market share in rehabilitation and expand sales of aesthetic medical products[6] - The company continues to promote technological innovation and product upgrades, successfully obtaining certifications for new devices[6] Investor Advisory - Investors are advised to be cautious as the financial data is preliminary and unaudited, with final figures to be disclosed in the annual report[9]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-001 南京伟思医疗科技股份有限公司 2023 年限制性股票激励计划预留授予部分第一个 归属期归属结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，南京伟思医疗科技股份有限公司（以下 简称"公司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《过 户登记确认书》，公司已完成公司2023年限制性股票激励计划（以下简称"本激 励计划"）预留授予部分第一个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序和信息披露情况 （1）2023 年 4 月 25 日，公司召开第三届董事会第十二次会议，会议审议 通过《关于<公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》《关 于<公司 2023 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提 请股东大会授权董事会办理股权激励相关事宜的议案 ...

根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2020〕1213号）文核准，公司向 社会公众公开发行人民币普通股（A股）17,086,667股，每股面值1.00元，每股 发行价格为67.58元。本次公开发行募集资金总额为1,154,716,955.86元，扣除总 发行费用91,729,995.18元（不含税），募集资金净额为1,062,986,960.68元。上 述募集资金到位情况已经天衡会计师事务所（特殊普通合伙）审验，并于2020 年7月15日出具了《验资报告》（天衡验字[2020]00075号）。募集资金到账后， 已全部存放于募集资金专项账户内，公司已与保荐机构长江证券承销保荐有限 公司及专户存储募集资金的商业银行签订了《募集资金三方监管协议》。 长江证券承销保荐有限公司 关于南京伟思医疗科技股份有限公司 部分募投项目延期的核查意见 上海证券交易所： 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上 市规则》《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》和《上海证券交易所科创板上市公司自律监管指引第1号—— ...

证券代码：688580 证券简称：伟思医疗 公告编号：2024-066 南京伟思医疗科技股份有限公司 第四届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届监事会第二次 会议通知于 2024 年 12 月 23 日以书面方式向全体监事发出。会议于 2024 年 12 月 26 日以现场结合通讯方式在公司会议室召开。本次会议由监事会主席胡平先 生主持，本次会议应出席会议监事 3 人，实际出席会议监事 3 人,本次会议的召 开符合《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等相 关法律、行政法规、规范性文件及《南京伟思医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 （一）审议通过《关于部分募投项目延期的议案》 南京伟思医疗科技股份有限公司监事会 2024 年 12 月 27 日 2 经审议，监事会认为：公司本次部分募投项目延期是根据项目实施的实际情 况做出的审慎决 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2024-065 南京伟思医疗科技股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京伟思医疗科技股份有限公司（以下简称"公司"）于 2024 年 12 月 26 日分别召开了第四届董事会第二次会议和第四届监事会第二次会议，审议通过了 《关于部分募投项目延期的议案》，同意将募集资金投资项目（以下简称"募投 项目"）"研发中心建设项目"、"信息化建设项目"及"康复设备组装调试项 目"达到预定可使用状态时间延期至 2025 年 12 月 31 日。 本次延期未改变募集资金投资用途、投资总额和实施主体，不会对募投项目 的实施造成实质性不利影响。保荐机构长江证券承销保荐有限公司对该事项出具 了明确的核查意见，该事项无需提交公司股东大会审议。现将本次部分募投项目 延期的具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1213 号） ...

证券代码：688580 证券简称：伟思医疗 公告编号：2024-067 南京伟思医疗科技股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第二次 会议通知于 2024 年 12 月 23 日以书面方式向全体董事发出。会议于 2024 年 12 月 26 日以现场结合通讯方式在公司会议室召开。 本次会议由董事长王志愚先生召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体监事和高级管理人员列席了会议。本次会议的召集、召开程序符合 《中华人民共和国公司法》等相关法律、行政法规、规范性文件及《南京伟思医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 董事会认为：本次部分募投项目延期是公司根据募投项目所在行业市场情况 和项目实际建设情况而做出的谨慎决定，有利于保证募投项目的建设成果更好地 满足公司发展规划要求。本次募投项目延期事项仅涉及募投项目达到预定可 ...

Company Overview - VISHEE Medical, established in 2001, is a high-tech medical device company headquartered in Nanjing, recognized as a national high-tech enterprise and listed on the Sci-Tech Innovation Board [1] - The company specializes in rehabilitation medicine, offering high-quality products and solutions in areas such as pelvic and postpartum rehabilitation, mental health rehabilitation, neurological rehabilitation, and pediatric rehabilitation [1] Financial Performance - For the first three quarters of 2024, the company reported total revenue of CNY 292 million, a year-on-year decrease of 12.06% [4] - The net profit attributable to shareholders was CNY 78.17 million, down 23.13% year-on-year [4] - After excluding stock payment and income tax impacts, the adjusted net profit was CNY 87.63 million, reflecting a decline of 20.92% compared to the previous year [4] Product Development and Market Position - The company has successfully developed and certified new products, including the MagNeuro ONE series of transcranial magnetic stimulators and various laser devices, enhancing its product matrix [4] - The high-frequency electrosurgical devices and shaping magnetic products have seen positive sales feedback in maternal and aesthetic markets, contributing to business transformation [4] - The mental health division continues to grow, establishing a mature treatment solution for physical therapy in mental health, solidifying its market leadership [4] Strategic Focus and Future Outlook - The company aims to adopt a pragmatic and long-term approach to R&D investments, focusing on risk control and organizational improvements to enhance performance [4] - Plans to expand into the silver economy sector with a diverse range of rehabilitation products targeting elderly patients, including cognitive function treatment software and rehabilitation robots [11] - The company anticipates that upcoming policies encouraging medical equipment updates will gradually stimulate demand, with expected performance improvements reflected in Q4 2024 and throughout 2025 [11] Technology and Innovation - VISHEE Medical has established six major technology platforms, including magnetic stimulation, electrical stimulation, and laser technologies, supporting a wide range of rehabilitation applications [9] - The newly certified ultra-pico laser device is the first of its kind in China, validated through extensive clinical trials, positioning the company competitively in the skin treatment market [8] Shareholder Engagement - The company has conducted share buybacks in 2022 and 2023, primarily for employee stock incentives, and is considering future buyback plans based on market conditions [15][16]

南京伟思医疗科技股份有限公司（以下简称"公司"）于近日收到了由江苏 省药品监督管理局颁发的 2 项《医疗器械注册证》，现将相关情况公告如下： 一、医疗器械注册证的具体情况 产品名称 多功能生物刺激反馈仪 型号、规格 VisheeNEO R200、VisheeNEO R210、VisheeNEO R220、VisheeNEO R300、 VisheeNEO R310、VisheeNEO R320、VisheeNEO R400、VisheeNEO R410、 VisheeNEO R420 注册证编号 苏械注准 20242092149 有效期至 2029 年 11 月 13 日 注册分类 II 类 适用范围 对肩周炎、肱骨外上髁炎、颈椎病、腰椎肩盘突出症、退行性骨性关节 病、风湿性关节炎、类风湿关节炎、捩伤、挫伤、肌纤维织炎、肌肉劳 损、狭窄性腱鞘炎、坐骨神经痛、周围神经伤病、关节挛缩具有消炎和镇 痛作用；对肌炎、骨折延迟愈合具有改善局部血液循环和促进炎症消散的 作用；对废用性肌萎缩、尿潴留、神经或肌肉伤病后肌肉功能障碍具有兴 奋神经肌肉的作用。对患者的体表肌电信号进行采集、分析和反馈训练， 可以对患者的肌肉施加电 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2024-063 南京伟思医疗科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。。 重要内容提示： | 回购方案首次披露日 | 2023/11/10，由董事长兼总经理、控股股东、实际 | | --- | --- | | | 控制人王志愚先生提议 | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元 2,000 万元~4,000 | | 回购价格上限 | 元/股（含），2023 年年度权益分派实施前， 63.42 | | | 为 90 元/股（含） | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 万股 42.5917 | | 实际回购股数占总股本比例 | 0.4447% | | 实际回购金额 | 2,003.766394 万元 | | 实际回购价格区间 | ...